STOKHIGH SIGNALOPERATIONAL10-K

STOK has progressed its lead drug zorevunersen from planned Phase 3 initiation to active patient dosing, with enrollment expected to complete in Q2 2026 and pivotal data anticipated in mid-2027.

This represents significant operational momentum for the biotech company, moving from pre-trial planning to active execution of its critical Phase 3 EMPEROR study. The company has shifted its strategic focus from trial preparation to rapid patient delivery, suggesting confidence in the development timeline and regulatory pathway for this Dravet syndrome treatment.

Comparing 2026-03-16 vs 2025-03-18View on EDGAR →
FINANCIAL ANALYSIS

The company's financial profile shows substantial improvement in profitability metrics, with losses meaningfully reduced across both net income and operating income despite notably higher R&D spending of $137.9M compared to $89.1M in the prior year. Total assets expanded to $418.4M while stockholders' equity grew to $352.5M, though cash reserves declined from $128.0M to $84.2M, reflecting the increased investment in clinical development activities. The overall picture suggests a well-capitalized biotech actively deploying resources toward its lead program while achieving better operational efficiency.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+92.3%
-$89.0M→-$6.9M

Net income grew 92.3% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+79.7%
-$101.4M→-$20.6M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Interest Expense
P&L
-65.4%
$26K→$9K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Total Liabilities
Balance Sheet
+55.1%
$42.5M→$66.0M

Liabilities grew 55.1% — significant increase in debt or obligations, assess impact on financial flexibility.

R&D Expense
P&L
+54.7%
$89.1M→$137.9M

R&D investment increased 54.7% — signals commitment to future product development, though near-term margin impact.

Total Assets
Balance Sheet
+54.1%
$271.6M→$418.4M

Asset base grew 54.1% — expansion through organic growth, acquisitions, or capital deployment.

Stockholders Equity
Balance Sheet
+53.9%
$229.0M→$352.5M

Equity base grew 53.9% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Liabilities
Balance Sheet
+44.5%
$40.1M→$57.9M

Current liabilities surged 44.5% — significant near-term obligations; verify ability to meet short-term debt.

SG&A Expense
P&L
+37.5%
$48.8M→$67.1M

SG&A up 37.5% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Cash & Equivalents
Balance Sheet
-34.2%
$128.0M→$84.2M

Cash declined 34.2% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

LANGUAGE CHANGES
NEW — 2026-03-16
PRIOR — 2025-03-18
ADDED
Zorevunersen is currently being evaluated in our global Phase 3 clinical study, EMPEROR, which was initiated in May 2025 , with the first patient dosed in August 2025..
We expect to complete enrollment of approximately 150 patients in the second quarter of 2026, with pivotal Phase 3 data anticipated in mid-2027 to support the submission of a New Drug Application ( NDA ) to the U.S.
We plan to initiate a rolling NDA submission in the first half of 2027.
This trial follows the completion of two open-label Phase 1/2a studies, MONARCH in the United States and ADMIRAL in the United Kingdom, and further evaluates the efficacy and safety of zorevunersen in children and adolescents ages 2 to up to 18 with Dravet syndrome.
The critical pillars of our strategy include: Deliver zorevunersen to patients as quickly as possible .
We have robust Phase 1/2a and ongoing OLE data supporting zorevunersen s long-term, disease modifying potential.
We have engaged with clinical sites to efficiently recruit patients and project data from our Phase 3 EMPEROR study by mid-2027.
In parallel, we continue to leverage Breakthrough Therapy Designation to engage with the FDA to identify opportunities to deliver zorevunersen to patients faster.
Expand capabilities to ensure successful commercialization of zorevunersen in the U.S., Canada and Mexico.
We continue to invest in our internal capabilities, with a focus on expanding our medical affairs and commercial teams.
REMOVED
Food and Drug Administration ( FDA ), European Medicines Agency ( EMA ), and Japan s Pharmaceuticals and Medical Devices Agency ( PMDA ), a Phase 3 study, EMPEROR, is expected to begin in the second quarter of 2025 to further evaluate efficacy and safety of zorevunersen in children and adolescents ages 2 to up to 18 with Dravet syndrome.
We have completed Phase 1/2a clinical trials for zorevunersen.
The critical pillars of our strategy include: Focus on rapid and effective execution of the Phase 3 clinical trial.
In addition, due to zorevunersen being granted Breakthrough Therapy Designation in the U.S., we have access to more intensive guidance from the FDA, which may help to expedite development.
Furthermore, we believe the announcements of Breakthrough Therapy Designation, recent clinical updates and regulatory alignment with the FDA, EMA and PMDA have catalyzed the Dravet syndrome community, and we have carefully selected and engaged with clinical sites to efficiently recruit patients.
Expand capabilities to ensure successful development and commercialization of zorevunersen in the U.S., Canada and Mexico and advance pipeline programs.
We are investing in focused organizational growth, especially in our medical affairs and commercial capabilities, to educate key stakeholders on Dravet and support launch readiness of zorevunersen.
We are focused on recruiting top commercial talent from across the rare disease space to effectively identify and access those patients who may benefit from our product candidates and educate healthcare providers on the benefits and risks of our medicines.
To further bolster these efforts, we entered into a collaboration for the development and commercialization of zorevunersen in all territories worldwide other than the United States, Canada, and Mexico (the Biogen Territory ).
1 Expand our pipeline by leveraging our proprietary TANGO platform and pursuing strategic collaborations to accelerate development of additional programs.
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →